Filtered By:
Specialty: Drugs & Pharmacology
Condition: Back Pain

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Orally Administered Crocin Protects Against Cerebral Ischemia/Reperfusion Injury Through the Metabolic Transformation of Crocetin by Gut Microbiota
Conclusion Collectively, pharmacokinetic and pharmacodynamic association studies provide evidence that the gut microbiota plays a vital role in the fate of crocin and crocetin in the gastrointestinal tract. In addition, the cross-interaction between gut microbiota and crocin might mediate the activation of the cerebral-protective effect of orally administered crocin. Ethics Statement This study was carried out in accordance with the recommendations of ‘Institutional Animal Research Committee guidelines, Animal Ethics Committee of China Pharmaceutical University.’ The protocol was approved by the ‘An...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions. Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

Description of Cardiovascular Event Rates in Patients Initiating Chronic Opioid Therapy for Noncancer Pain in Observational Cohort Studies in the US, UK, and Germany.
CONCLUSIONS: CV risk for new opioid users with ≥6 months of therapy was increased in patients with established CV disease compared with those without established CV disease, and the risk for specific outcomes differed by country. Assessment of CV safety events of new therapies introduced to chronic opioid users should consider sample size and population heterogeneity in the design of an observational study. PMID: 25033926 [PubMed - as supplied by publisher]
Source: Advances in Therapy - July 18, 2014 Category: Drugs & Pharmacology Authors: LoCasale R, Kern DM, Chevalier P, Zhou S, Chavoshi S, Sostek M Tags: Adv Ther Source Type: research

Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient.
Abstract Cobb Syndrome (Spinal Arteriovenous Metameric Syndrome 1-31 (SAMS 1-31)) is a rare, non-hereditary disorder. Approximately 100 cases of CS have been described to date. The actual incidence may be much higher since only symptomatic patients were documented. In particular, post mortem studies suggest a possibly higher incidence of this syndrome. The main clinical manifestations of this syndrome include skin stains of vascular nature on the torso, in combination with spinal vascular malformations localized in one and the same metameric or spinal segment. A rare diagnosis of this syndrome in patients over 18 ...
Source: CNS and Neurological Disorders Drug Targets - February 17, 2021 Category: Drugs & Pharmacology Authors: Putilina M, Teplova N, Dvornikov A Tags: CNS Neurol Disord Drug Targets Source Type: research

Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient
CNS Neurol Disord Drug Targets. 2021 Feb 17. doi: 10.2174/1871527320666210218083550. Online ahead of print.ABSTRACTCobb Syndrome (Spinal Arteriovenous Metameric Syndrome 1-31 (SAMS 1-31)) is a rare, non-hereditary disorder. Approximately 100 cases of CS have been described to date. The actual incidence may be much higher since only symptomatic patients were documented. In particular, post mortem studies suggest a possibly higher incidence of this syndrome. The main clinical manifestations of this syndrome include skin stains of vascular nature on the torso, in combination with spinal vascular malformations localized in one...
Source: CNS and Neurological Disorders Drug Targets - February 19, 2021 Category: Drugs & Pharmacology Authors: Marina Putilina Nataliya Teplova Anton Dvornikov Source Type: research

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
Study design and outcomes AbstractThe kynurenine pathway (KP) is the main path for tryptophan metabolism, and it represents a multitude of potential sites for drug discovery in neuroscience, including pain, stroke, and epilepsy. L ‐kynurenine (LKYN), the first active metabolite in the pathway, emerges to be a prodrug targeting glutamate receptors. The safety, tolerability, pharmacokinetics, and pharmacodynamics of LKYN in humans have not been previously investigated. In an open‐label, single ascending dose study, six part icipants received an intravenous infusion of 50, 100, and 150 µg/kg LKYN and new six participant...
Source: Pharmacology Research and Perspectives - March 8, 2021 Category: Drugs & Pharmacology Authors: Mohammad Al ‐Mahdi Al‐Karagholi, Jakob Møller Hansen, Dalia Abou‐Kassem, Anna Koldbro Hansted, Kumari Ubhayasekera, Jonas Bergquist, László Vécsei, Inger Jansen‐Olesen, Messoud Ashina Tags: ORIGINAL ARTICLE Source Type: research

Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders.
We described: (a) the protective and promyelinating effects of progesterone in experimental spinal cord injury, (b) the progesterone protective effects exerted upon motoneurons in the degenerating spinal cord of Wobbler mouse model of amyotropic lateral sclerosis; (c) the protective and anti-inflammatory effects of progesterone in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis and after lysolecithin demyelination; (d) the progesterone prevention of nociception and neuropathic pain which follow spinal cord injury, and (e) the protective effect of progesterone in experimental ischemic stroke...
Source: CNS and Neurological Disorders Drug Targets - September 4, 2013 Category: Drugs & Pharmacology Authors: De Nicola AF, Coronel F, Li G, Gargiulo-Monachelli G, McG Deniselle EY, Gonzalez SL, Labombarda F, Meyer M, Guennoun R, Schumacher M Tags: CNS Neurol Disord Drug Targets Source Type: research

Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review.
Abstract Cells of the immune system and the central nervous system are capable of interacting with each other. The former cell populations respond to infection, tissue injury and trauma by releasing substances capable of provoking an inflammatory reaction. Inflammation is a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and neuropsychiatric disorders such as anxiety/depression and schizophrenia. Neuroinflammation may also raise the brain's sensitivity to stress, resulting in stress-related neuropsychiatric disorders, such as anxiety or depression. The cytok...
Source: CNS and Neurological Disorders Drug Targets - November 30, 2014 Category: Drugs & Pharmacology Authors: Skaper SD, Facci L, Giusti P Tags: CNS Neurol Disord Drug Targets Source Type: research

N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update.
Abstract Neuroinflammation is a characteristic of a multitude of neurological and psychiatric disorders. Modulating inflammatory pathways offers a potential therapeutic target in these disorders. Omega-3 polyunsaturated fatty acids have anti-inflammatory and pro-resolving properties in the periphery, however, their effect on neuroinflammation is less studied. This review summarizes 61 animal studies that tested the effect of omega-3 polyunsaturated fatty acids on neuroinflammatory outcomes in vivo in various models including stroke, spinal cord injury, aging, Alzheimer's disease, Parkinson's disease, lipopolysacch...
Source: European Journal of Pharmacology - May 30, 2015 Category: Drugs & Pharmacology Authors: Trépanier MO, Hopperton KE, Orr SK, Bazinet RP Tags: Eur J Pharmacol Source Type: research

Convergent Phosphomodulation of the Major Neuronal Dendritic Potassium Channel Kv4.2 by Pituitary Adenylate Cyclase-activating Polypeptide.
Abstract The endogenous neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is secreted by both neuronal and non-neuronal cells in the brain and spinal cord, in response to pathological conditions such as stroke, seizures, chronic inflammatory and neuropathic pain. PACAP has been shown to exert various neuromodulatory and neuroprotective effects. However, direct influence of PACAP on the function of intrinsically excitable ion channels that are critical to both hyperexcitation as well as cell death, remain largely unexplored. The major dendritic K(+) channel Kv4.2 is a critical regulator of neu...
Source: Neuropharmacology - October 8, 2015 Category: Drugs & Pharmacology Authors: Gupte RP, Kadunganattil S, Shepherd AJ, Merrill R, Planer W, Bruchas MR, Strack S, Mohapatra DP Tags: Neuropharmacology Source Type: research

Proteomic Profiling in the Spinal Cord and Sciatic Nerve in a Global Cerebral Ischemia-Induced Mechanical Allodynia Mouse Model.
Abstract Central post-stroke pain (CPSP) is one of the complications of cerebral ischemia and neuropathic pain syndrome. At present, there are few studies of pain in regions such as the spinal cord or sciatic nerve in cerebral ischemic animal models. To identify proteomic changes in the spinal cord and sciatic nerve in global cerebral ischemic model mice, in the present study we performed an investigation using proteomic methods. In a comparison between the intensity of protein spots obtained from a sham and that from a bilateral carotid artery occulusion (BCAO) in spinal cord and sciatic nerve, the levels of 10 (...
Source: Biological and Pharmaceutical Bulletin - February 3, 2016 Category: Drugs & Pharmacology Authors: Harada S, Matsuura W, Takano M, Tokuyama S Tags: Biol Pharm Bull Source Type: research

Cannabinoid pharmacology in cancer research: A new hope for cancer patients?
Abstract Cannabinoids have been used for many centuries to ease pain and in the past decade, the endocannabinoid system has been implicated in a number of pathophysiological conditions, such as mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis, spinal cord injury, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity, and osteoporosis. Several studies have demonstrated that cannabinoids also have anti-cancer activity and as cannabinoids are usually well tolerated and do not produce the typical toxic effects of...
Source: European Journal of Pharmacology - February 4, 2016 Category: Drugs & Pharmacology Authors: Javid FA, Phillips RM, Afshinjavid S, Verde R, Ligresti A Tags: Eur J Pharmacol Source Type: research

Safety of medical treatments for endometriosis.
Authors: Berlanda N, Somigliana E, Viganò P, Vercellini P Abstract INTRODUCTION: All medical treatments for endometriosis are equally effective in relieving pain. However, all of them alleviate pain symptoms for as long as they are used, but pain always relapses when medication is discontinued. Therefore, medications need to be used in the long term. AREAS COVERED: Formulations of estro-progestins that contain less than 50 µg of estrogen are associated with a low risk of venous thrombosis, myocardial infarction and stroke. When considering the neoplastic effects, data suggest that the overall risk of invasiv...
Source: Expert Opinion on Drug Safety - February 17, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research